Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Ensure your covered population has access to Wegovy Undeniably powerful weight loss in both the pill and pen 1-3 Proven weight-loss efficacy in both pen and pill formats for adults with obesity or overweight with at least one weight-related comorbidity, in addition to diet and exercise Major cardiovascular event risk reduction that matters The only GLP-1 RA indicated for weight loss proven to help prevent life-threatening CV events for adults with established CVD and either overweight or obesity, along with diet and exercise 1,4,5 More ways to start than ever before Available in a once-daily pill or once-weekly pen , with broad access options for your commercially insured population and the lowest Wegovy self-pay offer yet 6 Explore the study information under Efficacy & Safety CV, cardiovascular
Marjot, T., Moolla, A., Cobbold, J
The 12 mg dose in TRIUMPH-4 led to a 28.7% loss over 68 weeks, while tirzepatide in the SURMOUNT-1 trial produced approximately 22.5% loss over 72 weeks
For a full breakdown of retatrutide adverse events beyond the injection site, see the retatrutide side effects guide
Avoid premature sports participation without functional testing
US$ 25.36
US$ 21.12
US$ 25.12
US$ 28.65
US$ 26.36
US$ 25.50
